Gönül ERDEN, Günay TEZCAN, Özden Ayşe SOYDAŞ, Metin Mustafa YILDIRIMKAYA

Biological variation and reference change value (RCV) of prostate specific antigen (PSA) levels in the serum of healthy young individuals

Amaç: Sağlıklı genç bireylerde prostat spesifik antijen (PSA) düzeylerinin birey-içi biyolojik varyasyon değerlerini saptamak ve bir bireydenard arda yapılan iki ölçüm arasındaki değişimin anlamlılığını değerlendirebilmek. Gereç ve Yöntem: Çalısmaya 26 sağlıklı gönüllü erkek [ortanca; yas aralığı,32,5 yıl (22-49)] alındı. Ondört günlük aralar ile her bireyden dördertane numune toplandı. Serum PSA düzeyleri kemiluminesan mikropartikül immün yöntem (CMIA) ile otoanalizörde çalışıldı. Bulgular: Total PSA’nın birey-içi biyolojik varyasyonu % 20,7 ve referans değişim değeri % 49,4 olarak bulundu (p

Sağlıklı genç bireylerde serum prostat spesifik antijen (PSA) düzeylerinin biyolojik varyasyonu ve referans değişim değeri

Purpose: The objectives of this study were to provide data about the intraindividual biological variations in prostate specific antigen levels for young men and to evaluate the significance of changes in serial results froman individual. Materials and Methods: The study group comprised 26 healthy male volunteers; median (range) age was 32.5 (22-49) years. Four blood sampleswere obtained from each subject, one at each 14-day interval. Serum PSAlevels were measured by a chemiluminescent microparticle immunoassay(CMIA) on a random-access analyzer. Results: The intra-individual biological variation for total serum prostatespecific antigen was 20.7%. The reference change value (RCV) for tPSAwas 49.4% (p

PDF

___

1. Ilic D, O’Connoe D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 3.Art. No.:CD004720.DOI: 10.1002/14651858.CD004720.pub2.
2. Lobel B. Screening for prostate cancer - how to manage in 2006? Acta Chir Iugosl 2005; 52: 19-21.
3. Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am 2003; 30: 209-217.
4. Oliver SE, May MT, Gunnell D. International trends in prostatecancer mortality in the PSA era. Int J Cancer 2001; 92: 893-898.
5. Piironen T, Pettersson K, Suonpaa M, et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen complexed to alpha 1-antichymotrypsin in blood samples. Urol 1996; 48: 81-87.
6. Yan Y. Intra-individual variation of prostate specific antigen measurement and implications for early detection of prostate carcinoma. Cancer 2001; 92: 776-780.
7. Fraser CG. Changes in serial results. The nature of biological variation. In: Fraser CG, ed. Biological variation: from principles to practice. Washington, DC: AACC Press, 2001: 67-90.
8. Stenman UH, Leinonen J, Zhang WM, Finne P, Wu P. The clinical importance of free prostate specific antigen. Curr Opin Urol 1998; 8: 393-399.
9. Soletormos G, Semjonow A, Sibley PEC, et al. on behalf of the European Group on Tumor Markers. Biological variation of total prostate specific antigen: A survey of published estimates and consequences for clinical practice. Clinical Chem 2005; 51: 1342-1351.
10. Hyltoft P, Fraser CG, Jorgensen L, Brandslund I, Stahl M et al. Combination of analytical quality specifications based on biological within- and between-subject variation. Ann Clin Biochem 2002; 39: 543-550.
11. Nixon RG, Wener MH, Smith KM, et al. Biological variation of prostate specific antigen levels in serum: An evaluation of daytoday physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997; 157: 2183-2190.
12. Glenski WJ, Klee GG, Bergstralh EJ, Oesterling JE. Prostate-specific antigen: establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation and the time on serum concentrations. Prostate 1992; 21: 99-110.
13. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989; 27: 409-437.
14. Ornstein DK, Smith DS, Rao GS, Basler JW, Ratliff TL, Catalona WJ. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997; 157: 2179-2182.
15. Talwar DK, Azharuddin MK, Williamson C, Teoh YP, McMillan DC, O’Reilly DSJ. Biological variation of vitamins in blood of healthy individuals. Clin Chem 2005; 51: 2145-2150.
16. Yildirimkaya MM, Bilgi C, Ozata M, et al. Biological variation of serum lipids and lipoproteins in patients with clinically well controlled non insulin dependent Diabetes Mellitus. Endocrine J 1996; 43: 345-351.
17. Boddy JL, Dev S, Pike DJ, Malone PR. Intra-individual variation of serum prostate specific antigen levels in men with benign prostate biopsies. BJU International 2004; 93: 735-738.
18. Brunn L, Becker C, Hugosson J, Lilja H, Christenson A. Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate 2005; 65: 216-221.
19. Price CP, Allard J, Davies G, et al. Pre- and postanalytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 2001; 38: 188-216.
20. Morote J, Raventos CX, Lorente JA, et al. Intra-individual variations of total and percent free serum prostatic-specific antigen levels in patients with digital rectal examination. Eur Urol 1999; 36: 111-115.
21. Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/mL range in male volunteers. J Urol 1996; 155: 1977-1980.
22. Browning MCK, McFarlane NP. Objective interpretation of results for tumour markers. J Nucl Med Allied Sci 1990; 34: 89-91.
23. Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem 2002; 35: 471-475.